# Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

> **NCT06289751** · PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Cervical Cancer
- Neoadjuvant Chemoimmunotherapy
- Radical Hysterectomy
- Extrafascial Hysterectomy

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Paclitaxel-albumin
- **DRUG:** Cisplatin
- **PROCEDURE:** Extrafascial hysterectomy
- **PROCEDURE:** Radical hysterectomy
- **PROCEDURE:** Cone biopsy

## Key facts

- **NCT ID:** NCT06289751
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-03
- **Primary completion:** 2026-03-01
- **Final completion:** 2031-01-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289751, "Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06289751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*